Apyx Medical (APYX) Stock Price
Apyx Medical Price
Over the last 19 years Apyx Medical grew revenue by 3.7% annually, reaching 52.84 M USD. Earnings per share have grown at 23.5% per year over the last 12 years. For Apyx Medical, the net margin of -21.2% is up versus -31.3% a few years ago. The consensus 12-month price target for Apyx Medical is 6.50 USD, about 169.7% above where the stock trades today. Of 12 analysts, 11 rate the stock a buy — an overall Buy consensus.
Apyx Medical stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Apyx Medical business model & stock analysis
Frequently asked questions about Apyx Medical
Apyx Medical Corp is a medical technology company focused on developing and commercializing innovative thermal surgical solutions. The company's business model revolves around the development, manufacturing, and sale of advanced energy surgical devices. Apyx Medical Corp's flagship product, J-Plasma®, utilizes a helium plasma technology to provide precise tissue cutting, coagulation, and ablation with reduced thermal spread. This cutting-edge technology is widely used in various surgical specialties, including gynecology, dermatology, and plastic surgery. Apyx Medical Corp aims to provide healthcare professionals with state-of-the-art solutions that enhance patient safety, improve outcomes, and optimize surgical procedures.
Apyx Medical Corp is primarily active in the medical technology industry. As a leading provider of innovative surgical solutions, Apyx Medical Corp focuses on advancing the field of cosmetic and surgical procedures. With their cutting-edge technology and expertise, they cater to a wide range of medical specialties including plastic surgery, dermatology, and gynecology. By offering high-quality products and groundbreaking technologies, Apyx Medical Corp plays a significant role in enhancing patient outcomes and revolutionizing the way surgical procedures are performed.
The main competitors of Apyx Medical Corp in the market include companies such as Medtronic, ConMed Corporation, and Ethicon. These companies also operate in the medical device industry, offering similar products and solutions. Apyx Medical Corp faces competition in areas like electrosurgery systems, advanced energy surgical devices, and cosmetic surgery and dermatology solutions, among others. It is important for investors and stakeholders to be aware of the competitive landscape in order to analyze market dynamics, evaluate company performance, and make informed decisions regarding Apyx Medical Corp.
Apyx Medical Corp, formerly known as Bovie Medical Corporation, is a leading medical technology company that develops and markets innovative energy-based surgical solutions. With a rich history dating back to its founding in 1926, Apyx Medical Corp has continuously evolved to become a global provider of cutting-edge medical devices used in various medical specialties. The company's dedication to research and development has resulted in the creation of advanced products like J-Plasma®, a low-temperature plasma technology used in surgical and aesthetic procedures. Apyx Medical Corp strives to deliver superior medical solutions, improving patient outcomes and advancing the field of healthcare worldwide.
Apyx Medical Corp, a leading medical technology company, has accomplished several significant milestones. The company launched its flagship product, Renuvion, a revolutionary device used for precision surgery in aesthetic and cosmetic procedures. Apyx Medical Corp also expanded its global footprint by securing regulatory approvals in key markets worldwide, including the European Union and Canada. The company's dedication to innovation and excellence led to multiple prestigious awards and recognition, highlighting its position as a market leader. Additionally, Apyx Medical Corp successfully established strategic partnerships with renowned healthcare institutions, fostering collaborative research and development initiatives. With these achievements, Apyx Medical Corp solidifies its reputation as a trailblazer in the medical technology industry.
Apyx Medical Corp is primarily present in the United States.
Apyx Medical Corp represents a set of core values and corporate philosophy that are integral to their mission. The company is committed to delivering innovative energy-based technologies for various surgical specialties, including cosmetic surgery and gynecology. Apyx Medical Corp focuses on providing safe, reliable, and effective solutions to healthcare professionals, ensuring patient satisfaction and well-being. With a dedication to continuous improvement and excellence, Apyx Medical Corp aims to advance medical advancements and elevate patient care standards. By prioritizing quality, innovation, and customer needs, Apyx Medical Corp remains a trusted leader in the medical aesthetics industry.
Analysts currently set an average price target of 6.50 USD for the Apyx Medical stock (median: 6.50 USD), implying +169.7 % versus the latest price. The consensus is based on 12 analyst ratings.
12 analysts currently rate the Apyx Medical stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Apyx Medical to generate revenue of 59.41 M USD and earnings per share of -0.22 USD.
Converted at the current exchange rate, the Apyx Medical share trades at 2.15 EUR (2.41 USD).
The Apyx Medical share (APYX) is listed on 3 stock exchanges, including: NASDAQ (APYX), Frankfurt (BOV.F), München (BOV.MU).
The Apyx Medical Corp is an internationally operating company that specializes in the development and marketing of innovative medical products. Its business model is focused on supporting doctors and medical facilities in improving clinical outcomes while optimizing patient results. The company specializes in three main areas: surgery, dermatology and aesthetics, and veterinary medicine. In surgery, the company offers innovative solutions to support operations. It utilizes ultrasound-based technology to make these processes faster, more precise, and safer. One of its most well-known products is the J-Plasma system, used in plastic surgery operations. This is a surgical instrument that allows doctors to perform precise incisions while minimizing bleeding and scarring. In dermatology and aesthetics, Apyx Medical provides solutions for skin treatment and improving outward appearance. One of its flagship products is the Renuvion J-Plasma handpiece, used in both dermatology and plastic surgery. This handpiece generates a plasma beam that rejuvenates the skin and reduces wrinkles. Additionally, Apyx Medical Corp also offers IPL systems, laser devices, and other tools for treating various skin conditions and removing hair and tattoos. Veterinary medicine is another important sector for the company. Apyx Medical provides solutions to improve animal treatment. The company has extensive experience in developing medical devices and instruments used in the veterinary field. These products are tailored to the needs of veterinarians and clinics, including surgical instruments, laser devices, and other tools for animal treatment. The business model of Apyx Medical Corp is based on the combination of research, development, and sales of innovative medical products. The company emphasizes close collaboration with doctors, clinics, and research institutions to understand customer needs and develop innovative solutions. Patient safety and health are at the forefront of the company's priorities. Apyx Medical Corp has a strong market presence in the United States, Europe, and Asia and aims to offer its customers innovative and high-quality solutions worldwide. The company continuously invests in research and development to expand its portfolio of innovative products and services and provide its customers with the best possible quality. In summary, the business model of Apyx Medical Corp aims to support clinical practice through the development and marketing of innovative medical products. The company offers solutions in three main areas: surgery, dermatology and aesthetics, and veterinary medicine. Close collaboration with customers and investment in research and development are key elements of this business model.
The expected revenue of Apyx Medical is 59.41 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Apyx Medical is -9.42 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Apyx Medical is currently -10.79. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Apyx Medical stock.
The price-to-sales ratio (P/S) of Apyx Medical is currently 1.71. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Apyx Medical stock.
The Eulerpool Quality Score for Apyx Medical is 4/10.
The ISIN of Apyx Medical is US03837C1062. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Apyx Medical is A2PBJC. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Apyx Medical is APYX. The ticker symbol is used to trade Apyx Medical shares on the stock exchange.
Apyx Medical stock
Apyx Medical Peer Group
Apyx Medical Ticker
Apyx Medical FIGI
All fundamentals and in-depth analysis of Apyx Medical
Our stock analysis for Apyx Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Apyx Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.